NIB-101

N/A

Report date: 2025/05/24 20:00:06

Base Information

Drug NameNIB-101

Drug Alias NameNIB-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGM2(ganglioside M2) inhibitors

TargetsGM2(ganglioside M2)

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNoile-Immune Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNoile-Immune Biotech Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A